ArticleFrontiers in immunology2026
Comprehensive metabolomic characterization of patients with myasthenia gravis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myasthenia gravis (MG) is mediated by abnormal antibody generation and is characterized by muscle weakness and pathological fatigue. However, the accuracy of anti-acetylcholine receptor (AChR) antibody testing for the diagnosis of MG needs improvement. Objective: This study was aimed to systematically characterize the plasma metabolome of patients with MG and identify novel biomarkers with significant diagnostic value. Methods: A cohort of 130 subjects was enrolled and divided into discovery and validation sets, and their plasma metabolomic profiles were determined by liquid chromatography-tandem mass spectrometry. Metabolomic variables were analyzed along with clinical information to identify relevant diagnostic biomarkers. The diagnostic efficacy of the screened metabolites and biomarker panel was assessed via receiver operating characteristic (ROC) curve analysis. Results: In positive and negative ion modes, plasma metabolomic profiling revealed 326 and 398 differentially abundant metabolites, respectively, in the discovery and validation sets. The metabolomic profile distinguished patients with MG from healthy controls across the two cohorts evaluated in this study. Furthermore, 890 metabolites were detected in both the discovery and validation sets. Metabolite set enrichment analysis of these 890 metabolites revealed that steroid hormone biosynthesis pathway was significantly enriched, implying that altered metabolism may serve as a potential pathological hallmark of MG. On the basis of the differences between groups, compound level, the value of the variable importance in projection, the area under the ROC curve (AUC) and precision-recall curve analyses, 3 differentially abundant metabolites, namely, LysoPE(P-18:1/0:0), PE(O-18:1/0:0) and PE(P-16:0/0:0), were selected as a biomarker panel to distinguish between patients with MG and healthy controls. ROC curve (AUC) analysis revealed that the biomarker panel and anti-AChR antibody testing had equivalent MG diagnostic ability (AUC: 0.883 vs. 0.825; Conclusion: Our screened biomarker panel discriminated patients with established MG from healthy healthy controls, however, further evaluation in independent cohorts including patients with suspected MG and other relevant autoimmune and neuromuscular junction disease healthy controls is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.